Many areas of southern, eastern England to see temperatures in 30s
More sweltering temperatures are also expected in southern and eastern parts of England on Tuesday, with many areas again passing above 30 Celsius with up to 36 Celsius expected locally, PA reported.
A tourist using a cold water can to try keep cool in the queue for the London Eye on the south bank in London. Photograph: Jill Mead/The Guardian
It comes after the UK Health Security Agency (UKHSA) extended amber heat health alerts for much of the country into Wednesday morning.
Monday saw the hottest start to Wimbledon on record, with 32.9C recorded at nearby Kew Gardens, while 33.1C was recorded at Heathrow.
Paris-Milan high speed line suspended after violent storms
Train travel between France and Italy is suspended for “at least several days” after violent storms earlier in the week, French national operator SNCF said, AFP reported.
The storms on Monday in southeastern France have forced a clean-up operation during which SNCF will check there has been no damage to tracks on the Paris-Milan high speed line which would prolong the closure, it said.
Italy adopts measures to deal with heat
In Italy, some regions, including Lazio and Lombardy, adopted new rules seeking to protect workers from record temperatures, requesting a halt to outdoor activities on construction sites and quarries during the hottest hours, according to national media. Other regions, like Emilia Romagna, are about to adopt similar measures this week.
People use umbrellas in hot weather to shelter from the sun while walking past the Colosseum, in Rome. Photograph: Andrew Medichini/AP
Elsewhere, in Genoa, free travel hours for senior citizens were extended to start earlier and encourage them to travel early before temperatures rise, Corriere della Sera reports.
Bologna authorities reported a 7% increase in the number of emergency calls.
Morning opening: It’s hot (again)
Jakub Krupa
Large parts of Europe are on extreme weather warnings again this morning as the first European heatwave continues, once again raising questions over public health, environmental hazards, and the impact of climate change.
Eighty-four departments are on orange heatwave alert, with temperatures likely to exceed 40 Celsius in some areas, a heatwave expected to last at least until midweek in Paris, France. Photograph: Sadak Souici/ZUMA Press Wire/Shutterstock
Paris (38C) is on the highest, red alert with the top of the Eiffel Tower closed to tourists as a precautionary measure. The country’s prime minister François Bayrou – who is separately facing a vote of no confidence today, which he is expected to survive – has cancelled his meetings to monitor the situation in real time.
Other cities across the continent will also see higher than usual temperatures, including Zaragoza (39C), Rome (37C), Madrid (37C), Athens (37C), Brussels (36C), Frankfurt am Main (36C), Tirana (35C), London (33C).
For some, it will be the peak of the heatwave; for others – it’s only the beginning.
I will bring you all the latest updates from across Europe here as the continent battles the heatwave.
It’s Tuesday, 1 July 2025, it’s Jakub Krupa here, and this is Europe Live.
Tamron has unveiled the 16-30mm f/2.8 Di III VXD G2, completing its trinity of f/2.8 zoom lenses for mirrorless cameras. The wide-angle zoom joins the existing 28-75mm and 70-180mm f/2.8 lenses in what Tamron calls its “Daisangen” collection.
According to the company, the lens features an updated optical design aimed at delivering high resolution across the frame while maintaining consistent f/2.8 performance throughout the zoom range. At just under one pound (453 g), the 16-30mm maintains the compact profile that has characterized Tamron’s G2 series.
Key Specifications
The 16-30mm covers ultra-wide to moderate wide-angle focal lengths on full-frame sensors, with an aperture range from f/2.8 to f/16. Tamron’s Voice-coil eXtreme-torque Drive (VXD) linear motor handles autofocus duties, providing quiet operation for video work.
Close focusing reaches 7.5 inches (19.05cm) at the wide end, enabling near-macro capabilities for environmental portraits and creative compositions. The lens accepts 67mm filters and features moisture-resistant construction with fluorine coating on the front element.
Tamron 16-30mm. Credit: Tamron
Mount Availability
The lens will be available in Sony E-mount at the end of July 2025, with the Nikon Z version following in August. Both versions support full autofocus functionality and communication with their respective camera systems.
Users can customize lens functions through Tamron’s Lens Utility software, which allows adjustment of focus ring behavior, focus limiter settings, and other operational parameters for both photo and video applications.
Tamron 16-30mm design. Credit: Tamron
Versatile Design
The lens measures 2.9 x 4.1 inches in diameter and length, making it well-suited for travel and content creation scenarios. The lightweight construction under one pound allows for extended handheld shooting without fatigue. Zoom and focus rings feature improved texture and smoother operation compared to previous generations.
Moisture-resistant construction protects internal components, while fluorine coating on the front element repels water and oil for easier cleaning in adverse conditions. The native Sony E-mount design ensures full compatibility with camera functions, and the 67mm front filter thread accommodates standard circular polarizing and neutral density filters.
Tamron 16-30mm. Credit: Tamron
Applications
The 16-30mm lens targets landscape, architecture, street photography, and astrophotography applications where the wide field of view and fast aperture prove beneficial. The constant f/2.8 aperture enables consistent exposure settings across the zoom range, while the wide aperture aids low-light shooting and shallow depth of field effects.
The lens completes Tamron’s three-lens f/2.8 zoom system, providing focal length coverage from 16mm to 180mm for photographers seeking a compact alternative to larger first-party options.
Pricing and availability
The new lens is now available for pre-ordering at B&H for $929.
Are you a Tamron user? If so, how do you like their lenses? Do you see yourself purchasing this new wide-angle lens? Please share your thoughts with us in the comment section below.
Incoming Chinese competition is an ominous sign for one of Europe’s last clean technology hopes—wind turbine manufacturing.
China has already eradicated Europe’s solar industry. It also dominates the supply chains of many components and raw materials crucial for wind turbines.
At this rate, the decarbonisation of the EU’s power generation sector could become yet more dependent on Chinese renewable technology.
Europe can still save its wind industry. But policymakers will have to take more decisive action to ensure fair competition in Europe for domestic and foreign firms alike.
They also need to ensure predictable, long-term demand and work with like-minded partners to build resilient supply chains that can weather future shocks.
Headwinds
Europe’s wind turbine manufacturers were industry pioneers. Their cutting-edge technology still dominates in the EU, and it captures a large slice of the pie in the United States and in many emerging markets. But Europe’s wind industry is in trouble. After years of rapid growth at home, Chinese manufacturers are expanding overseas and encroaching on markets European companies have long led, including in the heart of Europe itself.
The EU has launched initiatives to support Europe’s manufacturers as they grapple with incoming competition from Chinese firms. But without more decisive action, Europe’s wind sector could fall prey to the “second China shock”. The first of these upheavals happened after China joined the World Trade Organization (WTO) in 2001 and flooded rich economies with cheap consumer goods, contributing to a decline in manufacturing jobs—particularly in the US. The second round could well be more consequential for Europe: this time, it is high-value sectors at risk.
China’s growth in advanced manufacturing stems from tightly integrated local supply chains, abundant resources and access to world-class engineering talent. But it also benefits from Beijing’s massive and diverse range of state support. This means Chinese firms enjoy baked-in advantages over their Western competitors as they hit the global market—notably, the economies of scale China’s vast closed market brings and abundant supplies of low-cost products. Chinese competition has already eradicated Europe’s (also pioneering) solar industry. And China dominates supplies of many components essential in wind turbine manufacturing. The danger for the EU is thus not only that decarbonisation leads to deindustrialisation through a loss of European jobs and exports; the bloc will also face a new kind of energy security risk: dependence on Chinese renewable technologies.
The EU and European governments need to work with Beijing on trade and climate. But they will only expose themselves to geopolitical leverage if they fail to balance this necessity with China’s status as Russia’s “no limits” partner and what NATO has labelled a “decisive enabler” of Russia’s war on Ukraine. Disruptions to energy supplies, once rare, have become recurring features in a world increasingly shaped by geopolitical rivalry. Recent history lays bare how over-dependencies in energy, trade and security—on any single source—can, and will, be weaponised by foreign powers. As Europe reduces its dependence on Russian fossil fuels, it would be an act of cognitive dissonance if it did not manage the risks of dependence on clean energy technologies from China.
The second Trump presidency has already made matters worse. The 2022 US Inflation Reduction Act (IRA)—landmark legislation designed to boost domestic clean technology manufacturing—created new opportunities in the US market for European investors and manufacturers. But these opportunities may disappear, for instance, under Trump’s “One Big Beautiful Bill Act”. This, as well as tariffs and a volatile trade war, means European wind developers have found their access to the US market is in jeopardy and their financial health squeezed when they are already warming up to buying Chinese wind turbines overseas and in Europe.
Europe can, and should, save its wind turbine manufacturing industry. This policy brief aims to guide European policymakers and industry figures in this process. First, the paper underscores the potential of Europe’s wind turbine manufacturing industry to continue to thrive, but also some of the problems it faces—including supply chain dependencies on China. It then examines how Beijing’s industrial policy created such immense scale in its homegrown wind turbine manufacturers that they can undercut European firms as they expand into the global market, potentially also undermining Europe’s energy security.
Ultimately, the brief argues that Europeans should focus on three overarching policy goals to ensure Europe’s manufacturers keep their place in the world’s energy transition:
make Europe the world’s most (genuinely) competitive market for wind energy—including for Chinese companies;
ensure that market enjoys predictable long-term demand;
develop diverse, resilient supply chains and a robust industrial base that can weather future shocks.
Europe’s big clean breeze
In 2024, European wind turbine manufacturers play a large role in making—especially assembling and installing—almost all turbines on the continent. This dominance, and the industry’s notable manufacturing capacity, means it is a significant jobs creator among renewable sectors in Europe.
The industry’s strong position in Europe is underpinned by decades of global leadership and technological competitiveness from manufacturers, suppliers, and collaborating research centres and universities. The global strength of European wind turbine manufacturers brings more than economic and energy security benefits: it also contributes to Europe’s strategic autonomy—ensuring that some decisions about the world’s energy transition are “made in Europe” too.
At home
The green transition in Europe is highly dependent on wind power. In 2024 wind surpassed natural gas in power generation for the first time, accounting for 18% of the EU’s electricity mix. If the EU meets its targets, wind is set to supply over a third of the bloc’s electricity needs by 2030 and half of its power demand by mid-century. Wind is already helping wean Europe off Russian gas, and it will play a key role in shielding the continent from the volatility of global fossil fuel markets. Wind power and Europe’s wind industry are therefore central pillars of European energy security. And the European wind market holds great potential and opportunity.
Yet, political polarisation and the “greenlash” of recent years mean future demand for wind power is not guaranteed. Renewables are cheaper than fossil fuels, but it takes time and investment for people to feel that saving in their pockets. Governments, meanwhile, are also feeling the pinch following the covid-19 pandemic and Russia’s war against Ukraine. A key economic benefit of and social licence for net-zero policies is green jobs. The implementation of the EU’s European Green Deal could create 2.5 million of these by 2030. But these jobs are not an inevitable result of the energy transition. In 2024 alone the European car industry cut 88,000 jobs amid its shift to electric vehicles. The 2025 bankruptcy of Swedish company Northvolt, once Europe’s best hope as a battery manufacturing champion, has cast doubt on the future of the continent’s battery industry.
Europe’s wind turbine manufacturing industry—the world’s second largest after China—is far more promising. Including Norway and the UK, it employs 370,000 people, primarily in Germany, Spain, France and Denmark. By 2030, the workforce in just the EU could grow to 936,000, accounting for 16% of the potential new green jobs. Unlike the solar industry, in which most of the job potential comes from the installation of the technology, manufacturing accounts for the majority of the jobs in wind—with demand set to grow. These jobs will not all necessarily disappear as Chinese competitors enter the European market, particularly if they decide to produce components locally. But Europe will lose technological sovereignty if it does not ensure its manufacturers survive.
And abroad
The past 15 years have seen the Chinese market replace that of the EU as the epicentre of the global wind industry. In 2010 China became the country with the largest single wind market in the world. It took just five more years for the country to overtake the EU’s then 28 member states combined. And it has shown no signs of slowing down since then: by 2024 the Chinese market accounted for 70% of new wind installations, an increase from over 60% of the world total in 2023.
Indeed, 2024 was the first year on record that Western wind turbine makers did not rank in the top three wind turbine suppliers. Chinese manufacturers Goldwind, Envision, Windey and Mingyang accounted for four of the top five largest wind turbine producers in the world. Goldwind alone brought online over 19 gigawatts (GW) of wind turbines. This is nearly 16% of the world’s total and enough to power the whole of Belgium (on a very cold day). At over 10GW, the Danish company Vestas took fifth place.
For now, this remains largely due to Chinese manufacturers dominating in their colossal home market. European wind turbine manufacturers still lead in almost every other part of the world. Indeed, wind is one of the few remaining clean technology sectors in which European companies—Vestas, as well as German-Spanish firm Siemens Gamesa and Germany’s Nordex, for example—maintain a sizable global market share. Besides their dominance in Europe, they also enjoy a strong position in the US and a solid presence in other markets. In 2024, Vestas alone held close to one-third of the global market share outside China.
The EU also enjoys enduring leadership in innovation and technological development. This is despite China’s gains on this front. Since 2009 China has consistently filed more wind patents than any other individual country and EU member states combined. These inventions, however, tend not to be protected outside the Chinese market; nor do they hold significant economic or strategic value for their owner (“high value” patents). Between 2019 and 2021, the EU remained the global leader by some distance on numbers of high-value patents, with Denmark and Germany taking first and second place. (The US was third, and China fourth.) Patenting specifically for offshore wind technology focuses on new technologies such as floating foundations. This has followed a similar pattern to onshore and offshore inventions combined: in 2023 China led in overall numbers of patents but lagged behind Germany, Denmark and the US for international filings.
But innovation in the wind sector is moving beyond blades, rotors, gearboxes and other key components. To improve the efficiency of turbines and wind farm management, manufacturers are developing energy storage and hydrogen conversion, as well as digital technologies such as AI, big data analytics and machine learning. This next wave of technological advances presents opportunity for Chinese manufacturers to close the innovation gap with their European competitors as they expand overseas, just as they have in other clean technology industries.
The security and economic benefits Europe is set to gain from renewables will be undermined if the continent becomes dependent on one source for clean technology—whether that is China or anywhere else. Solar energy, for example, provided around one-tenth of the EU’s electricity needs in 2024. But 95% of solar panels installed in Europe are imported from China, which also dominates the production of polysilicon (a critical component of solar cells). In 2023, Europe made up 14% of the world’s wind turbine value generation. This is, however, mostly in design engineering and assembly. To protect jobs and mitigate supply chain risks, the EU will have to hold onto this—but also expand its manufacturing base and diversify its suppliers.
China, meanwhile, accounts for over 60% of the global manufacturing value in wind turbines. China dominates key components such as gearboxes, generators, power converters and castings. It also controls the production of subcomponents and raw material extraction necessary to make turbines, such as 90% of permanent magnet manufacturing and 62% of global rare earth mining.
European countries are making some progress in developing their domestic rare earth processing and magnet making industries. France and Norway, for example, have begun developing their rare-earth processing capacity; Estonia is in the early stages of magnet manufacturing. But the need for these critical minerals and magnets will only grow. All offshore wind turbines require rare earth magnets (as do up to 30% of onshore turbines). And offshore wind installations are expected to make up 50% of the EU’s total by 2030, up from 31% currently.
Such dependencies mean the EU faces strategic risks in reaching its renewable energy targets. Supply disruptions in China would not immediately upset Europe’s energy system like a Russian gas embargo. But decisions about the cost and pace of the EU’s green transition could become contingent on policy choices made in Beijing. After all, China has increasingly used export controls to maintain its dominance in clean energy supply chains. As early as 2020 Beijing reportedly placed informal high-grade graphite (a mineral crucial in the production of lithium-ion batteries) restrictions on Sweden, home to the bankrupt Northvolt. It made these restrictions official for all exports of high-grade graphite in December 2023. In early 2025, China imposed controls on tellurium, tungsten and indium—critical materials for solar cell production.
Unpredictable demand
The accelerating energy transition has triggered a race for seemingly ever larger, more powerful wind turbines. European manufacturers are very much in this race. But Chinese firms lead in the development and prototyping of the world’s largest offshore wind turbines, with Dongfang testing a model whose rotor blades span 310m in diameter—nearly the height of the Eiffel Tower.
The sheer scale of these turbines and their components necessitates costly upgrades to factories, vessels and ports. The arms race in turbine size also means products more quickly go out of date. This forces manufacturers to invest heavily in research and developments (R&D), straining cash flows. European industry figures have warned that Europe’s infrastructure is not ready for much larger turbines. They instead favour expanding the production of existing models as a more sustainable approach in which the goalposts are more static.
Moreover, the EU is having to overcome regulatory hurdles to that add to the uncertainty. Europe’s wind manufacturers have been stymied, for instance, by longstanding problems with permitting for new wind farms and connection to the grid. The EU and member states have begun to address this through initiatives to simplify the permitting process and make it more efficient. Moreover, in recent years some European governments have applied “negative bidding” in their tenders, where the investor essentially pays for the right to develop a project. While this proved attractive to some member states, high costs and supply chain disruptions since the covid-19 pandemic have since turned many European investors against this approach: Denmark’s large offshore tender in late 2024 received no bids, for example. When investors do pay, the extra costs end up being passed on to turbine manufacturers, suppliers and customers. Negative bidding also favours low-cost, high-scale Chinese competitors, despite the potential risks to economic and energy security.
And Trump
The second Trump administration complicates things further. Since his return to the US presidency, Donald Trump has launched an aggressive and volatile trade war that threatens to upend the international trading order. Trump’s tariffs have elicited a response from China. In April, for example, Chinese authorities imposed restrictions on rare earth elements and permanent magnets. This did not only affect the US, but also European importers.
Trump has also sought to roll back support to clean technology manufacturing, increasing uncertainty for European wind companies in the US. Democrat-led and even some Republican states continue to support clean energy incentives under the IRA, which may keep onshore wind development moving forward. But offshore wind projects, which were already facing delays and cancellations, will likely be hit by federal regulatory shifts that hinder their progress even more. In face of such risks, analysts warn of a “wait and see” attitude among European investors. This uncertainty, and potential loss of US revenues, is nudging EU wind developers towards engaging more closely with cheaper Chinese wind turbine manufacturers in European and overseas markets.[1]
China’s global hurricane
There is good reason for Europe’s wind industry to fret over incoming Chinese competition. Chinese wind companies not only provide competitive and innovative products, but thanks to China’s competitive domestic wind market and subsidised manufacturing positions all along the supply chain, a Chinese-made turbine costs at least 30% less than those made by European and American companies. This means Chinese manufacturers could be on track to dominate another global industry, undercutting European incumbents in markets such as India and very possibly in Europe itself.
First China
Historically, Chinese wind manufacturers were dependent on Western pioneers. Technology transfer took place through commercial licensing, joint technology development and acquisition deals. But, as with solar panels, China’s subsidies and protectionist policies over the last three decades have given Chinese companies a significant boost, shutting European competitors out of China. In 2005, for example, Siemens Gamesa enjoyed a one-third stake in China’s wind market; by 2010, that had shrunk to a mere 3%. This exclusion has played an important role in shaping today’s challenges for European wind turbine manufacturers, as it denied European firms the opportunity to benefit from the economies of scale that China’s wind industry giants now enjoy.
China’s leaders started their localisation drive for the wind sector as early as 1996, when they introduced local content requirements, mandating that wind farms include a minimum of 20% Chinese-made parts. This rose to 50% in 2003 and 70% by 2005. They also prioritised wind farms that used local content for permits and then connection with the grid. The aim of this drive was not only to ensure Chinese companies captured a larger part of the profits from the wind turbine supply chain, but also to “import, digest and absorb” advanced technologies to enable “self-development of wind energy intellectual property”.
Western wind turbine makers, in turn, found good reasons to encourage their foreign suppliers to set up shop in China. One key disadvantage foreign bidders experienced was that Chinese government tenders in the wind power sector often focused on initial turbine price but not life-cycle cost. And, to access the Chinese market and receive government funding, foreign wind turbine manufacturers had to form joint ventures with local Chinese companies and transfer wind turbine technology. As they did this, their market share in China was increasingly squeezed by policies that favoured Chinese domestic firms. In 2009 Beijing dropped its 70% local content requirement to signal to Western governments that China was a competitive market. But European manufacturers have reported they were still rejected after that due to requirements for Chinese-made parts.
The Chinese government also introduced subsidies that targeted Chinese-owned wind turbine manufacturers. For instance, the “Special Fund for Wind Power Equipment Manufacturing” offered grants “to Chinese-funded and Chinese-controlled” wind equipment manufacturers that also used components made in China. But Beijing cancelled this fund in 2011 after the US challenged it at the WTO on the basis that it amounted to unfair subsidies. By that time, however, Chinese manufacturers already dominated their domestic market. Now, non-Chinese turbine manufacturers barely register in China’s wind industry. While European and American wind turbine manufacturers still account for about 10% of turbine production in mainland China, most of these products are exported. Just 0.2% are made for the Chinese domestic market. Western manufacturers are thus producing in, but not for, the world’s largest wind market.
China’s wind turbine manufacturers, meanwhile, benefit from tightly integrated local supply chains, abundant upstream resources such as rare earths, and access to world-class engineering talent. But intense price wars and the end of some government incentives have slashed the profit margins of Chinese wind turbine manufacturers. This, and a turbine surplus of around 20GW in 2024, has intensified Chinese manufacturers’ search for more profitable opportunities abroad.
Then emerging markets
Most of the world’s wind power is generated in China, European countries and the US. But new markets have begun to emerge over the past couple of decades. European wind turbine makers maintain a strong position in most of these emerging markets, though industry insiders fear that the wind industry outside China is reaching a tipping point.[2] In the years that followed the covid-19 pandemic, Western wind turbine makers faced persistently higher costs due to supply chain disruptions and inflation. Most companies responded by turning to their home markets where they can sell fewer products at a higher price (and did not bid for less profitable tenders in emerging markets). On top of these sector-wide difficulties, Siemens Gamesa suffered serious product quality problems.
This does not mean a Chinese takeover of the world’s wind industry is guaranteed. The vast majority of new installations by Chinese companies remain in China. But they are advancing overseas. In 2023 Chinese wind turbine makers won overseas orders for 7GW in capacity—more than the previous three years combined. This is equivalent to 15% of the market outside China. They already enjoy a big slice of Central Asian markets, and have overtaken European firms in the Middle East and Africa. Now, Chinese wind turbine manufacturers are displacing their Western competition in larger emerging markets too.
India has become the largest wind market outside China, European countries and the US. Even before the pandemic-related supply chain disruptions, Vestas and Siemens Gamesa had built a presence in India as a de-risking option from China. Nordex exploited its Indian production in 2024 for exports to Europe. But some Chinese wind turbine manufacturers are also expanding their footprint in the Indian wind industry. In recent years, Envision has opened a casing factory in Maharashtra and a blade factory in Tamil Nadu, in addition to developing partnerships with Indian and foreign suppliers.
Indeed, India is a prime example of how quickly the tables can turn on European manufacturers. For years, Siemens Gamesa and Vestas often held nearly half of the annual Indian wind market. But the 45% market share they held in 2019 has collapsed, with China’s Envision rising to become the dominant firm with a 41% share, roughly the same as local manufacturers Suzlon (20%), Inox Wind (15%) and Adani Green (7%) combined. Another Chinese company, Sany, is also increasing its share.
This marks an abrupt sidelining of Western wind companies. (By March 2025, owing to its broader financial struggles, Siemens Gamesa was in the process of selling much of its India business.) The sheer scale Chinese wind turbine manufacturers command at home makes their international offerings cheaper than foreign and Indian wind companies. According to Indian wind-industry insiders, Chinese firms also provide fixed rather than variable price contracts because their sizable stock largely shelters them from price fluctuations.[3] Indian wind turbine manufacturers have called for “fair play” in face of a foreign “invasion” of the wind sector (including by Western manufacturers).
Brazil is another battleground. Although Vestas and Nordex currently lead with about 70% of the Brazilian market, China’s Goldwind has opened a turbine plant in the country, positioning itself for rapid growth across Latin America thanks to greater ease in transporting massive components.
And finally, Europe
The EU market could be next. By 2022 Mingyang turbines were already in action off the coast of Italy; Croatia had an onshore farm complete with turbines manufactured by Shanghai International. Chinese manufacturers see many such opportunities in the thriving EU market, where a record 16GW of new capacity was installed in 2024. Given Chinese manufacturers only took roughly 1% of the EU wind market that year, they have a long way to go. But the rapid ascent of Chinese manufacturers in solar, telecommunications and other clean technology and digital industries should provide ample cause for concern among European leaders and wind manufacturers.
Chinese turbine manufacturers are engaging European investors and taking steps to establish a stronger presence and production base in Europe. European investors have also been attracted by the low-cost advantages of Chinese wind turbine makers for their projects outside Europe, particularly since many Western manufacturers downsized their global ambitions after the covid-19 pandemic. French, Danish, Italian and other European investors have already chosen Chinese wind turbine makers for projects in emerging markets—including on the EU’s doorstep. In 2023, for example, Windey won close to 1GW of deals in Serbia from the Italian company Fintel Energia.
Chinese manufacturers see these projects as a way to demonstrate their products’ performance and reliability to European and international developers.[4] Once the Chinese turbines have built up a two- to three-year track record of performance in overseas projects, wind analysts argue, European investors will be better placed to assess whether Chinese manufacturers compete as well in practice as they seem to on paper.[5] European developers are not blind to demands for a secure green transition in Europe. But others in the industry fear that, if these “test projects” go well, Chinese manufacturers will win more and larger EU-based wind energy projects and their European counterparts will suddenly find themselves with shorter order books and shrinking share prices.[6]
Indeed, in 2024 European investors chose Mingyang to supply turbines for offshore wind projects in the North Sea and the Mediterranean. As part of a collaboration with energy developer Renexia, Mingyang has also signed a deal to build a turbine factory in Italy. Moreover, a division of Goldwind plans to open a factory in Spain, and the company has joined a host of other Chinese players bidding for new offshore projects in France. Still, Chinese wind turbines remain largely unproven in European markets. And the rapid rollout of new and larger Chinese models has raised concerns among some investors.
The potential damage
The EU has started the damage limitation. Among the raft of initiatives is the flagship 2023 Wind Power Package that aims to strengthen domestic manufacturing and stimulate local demand through strategic public procurement. This initiative covers permitting reform and auction design, but also finance and skills to help Europe maintain its “first mover” advantage in wind and fill all those future jobs. The 2024 Net Zero Industry Act and 2024 Clean Industrial Deal also aim to boost domestic manufacturers and demand. These efforts are starting to bear fruit. Besides the EU’s record installations in 2024, over 30 new wind turbine manufacturing facilities had been announced across the continent by the end of the year. EU financial instruments, including the European Investment Bank (EIB) and the Innovation Fund are now supporting wind manufacturing projects in Europe.
Moreover, the European Commission has taken a more proactive stance on unfair trade practices. In 2024 it launched an investigation into wind projects involving Chinese turbine suppliers suspected of benefiting from market-distorting subsidies. This year it also introduced provisional duties on imports of epoxy resins, used in wind turbine blades and other products, from China and other Asian countries. Back in 2021 it imposed anti-dumping measures on Chinese steel wind towers. One component supplier, however, said EU tariffs are leading Chinese companies to relocate to other markets, like Turkey, to produce there and circumvent the levies.[7]
Without more decisive action, the expansion of Chinese turbine manufacturers will have serious market-distorting effects in the EU’s wind industry and could imperil its energy security.
Economy
Chinese wind turbine makers can offer European customers multiple years of deferred payment—generous conditions European wind companies simply cannot match because they are beholden to bottom lines. Chinese manufacturers’ edge is also bolstered by direct government subsidies in the form of income-tax concessions, grants and below-market borrowing rates, which amount to about 4% of the firm’s revenue on average. OECD wind turbine manufacturers on average receive subsidies amounting to about 1% of their revenue.
The presence of Chinese wind turbine manufacturers in the European market does not necessarily mean European jobs will disappear, if they decide to produce components locally. However, the economic value of Chinese investments will largely depend on Beijing’s policy decisions. China’s government, for instance, has instructed car companies investing in Europe to retain advanced electric vehicle (EV) technologies within China. It has also encouraged the use of “knock-down kits” (pre-assembled, domestically produced components for final assembly abroad) as a means to safeguard economic activity and intellectual property in China. Similar dynamics are evident at EV manufacturer BYD’s plant in Hungary, which relies on importing battery cells and steel from China. This limits its economic benefit for the country and hampers the development of local supply chains.
Security
The contribution of wind power to Europe’s energy security is based on a well-functioning and secure wind industry. China already dominates supply chains in solar and in components crucial to the wind sector. If the EU seriously considers China a “systemic rival” then it will have to counter security risks all along the renewables supply chain. This includes wind turbines, which remain its best hope to avoid hyper-dependency on China.
The European defence and intelligence communities have raised concerns over the presence of Chinese wind turbines in Europe. A German defence ministry think-tank has advised against the development of wind farms using Mingyang turbines. And the British departments of defence and energy security reportedly objected to the inclusion of Chinese manufacturers in a wind farm tender in Scotland.
Wind farms—especially offshore installations—rely on remote monitoring and control systems (given their locations). Indeed, manufacturers can typically shut off their turbines anywhere in the world within an hour. Such vulnerabilities, whether they are deliberately embedded or not, can be exploited by hostile actors or firms under state pressure. China’s 2017 National Intelligence Law, for instance, compels all companies to cooperate with the country’s intelligence services. Off-site access could be exploited as a point of entry, to disguise an attack as maintenance through software updates. Such breaches could create a voltage depression that destabilises the grid, or, in the worst-case scenario, cause serious physical damage to turbines. Beijing, in turn, recently ensured one Western manufacturer could no longer remotely control its China-based turbines.[8]
This remote access also means wind farms are vulnerable to cyberattacks, regardless of where the technology comes from. On the day Russia invaded Ukraine, German wind turbine maker Enercon lost remote access to 5,800 turbines after a Russian-linked cyberattack on a communication satellite. While an attack on Europe’s power systems would likely only happen in a moment of extreme geopolitical tension, as it could be interpreted as an act of war, that does not negate the risk altogether. The US has accused a Chinese state-backed group of cyber actors, Volt Typhoon, of infiltrating critical infrastructure to map vulnerabilities that could be exploited in the event of a military conflict. This includes America’s energy systems.
How to keep the wind in Europe’s sails
Europe faces mounting demands on its political and financial capital: higher defence spending, the economic aftershocks of the so-called Trump tariffs, and intensifying industrial competition from China. Among all this, European policymakers would do well to prioritise the wind sector. Strengthening European wind manufacturing is not just about corporate market share; the sector will also play a crucial role in the continent’s economic prosperity, energy security and strategic autonomy.
In saving Europe’s wind industry, policymakers and industry figures should focus on three overarching goals: first, making Europe the world’s most (genuinely) competitive market for wind energy; second, ensuring that market enjoys predictable long-term demand; and third, developing resilient supply chains and a robust industrial base capable of weathering future shocks. To achieve these goals, policymakers should consider the following recommendations.
Forging the world’s most competitive wind energy market
Restore fair competition
The aim of trade defence measures is to ensure business in Europe takes place on a level playing field and involves fair competition for all firms, domestic and foreign. It is not to exclude Chinese firms from the European market. EU policymakers should therefore aim to offset the distorting effects of Beijing’s state support to its wind industry overseas. This will enable the EU to keep its market open to Chinese trade and investment that meets fair competition criteria, meaning European manufacturers benefit from competition and investors retain access to the best technology worldwide.
In 2024, for instance, the EU imposed tariffs on Chinese EVs, and the ensuing row may very well lead to agreements on pricing and local production. This shows how trade defence measures can potentially be an effective lever in negotiations to restore fair competition. Europe’s wind market may not be the largest, but policymakers should aim for it to be the most pro-competition in the world.
Insist that foreign investment creates significant local value
Member state governments should ensure that foreign direct investment (FDI) brings about growth in wind manufacturing in Europe as well as local value creation. This means they need to prevent their wind industries becoming mere assembly hubs for Chinese components.
European governments should adopt a coordinated approach to negotiating, vetting and conditions for FDI in wind and other clean technology. They should focus these efforts on safeguarding local interests and prioritising local supply chains, workforce development and technology transfer, while maintaining fair competition for European and foreign firms. As part of this, the European Commission should include greenfield investments in renewable energy manufacturing, such as factories for wind turbines and their components, in its ongoing update of the EU FDI Screening Regulation (which enables the commission to advise member states on foreign investment).
But, as member states negotiate deals and apply screening mechanisms, governments must keep in mind that Chinese companies operate within the framework of Beijing’s broader geopolitical and foreign policy goals. Beijing has already said that Chinese companies should favour investment in EU countries that oppose tariffs on electric vehicles and freeze projects in member states that support them. This includes those companies operating as private enterprises. In March 2025, for example, Hong Kong-based conglomerate CK Hutchison attempted to sell its stakes in Panama ports likely to avoid any Trump-related business complications. This attempt, however, was abruptly halted following intervention from China’s regulator, underscoring the fact that private firms remain subject to Beijing’s strategic considerations and control.
Ensuring predictable demand for long-term investment
Pause the “battle for the biggest”
European governments and industry should explore setting standards on turbine size through the European Commission’s high-level forum on European standardisation. They should also adjust tender auction designs to avoid systematically favouring ever-larger models. This will help prevent the goalposts constantly moving (and expanding) and mitigate the challenges of giant untested turbines. To ensure measures such as these do not stifle innovation, the wind industry should also develop predictable timelines for when new standards would allow increases in turbine size.
Prevent a “race to the bottom” in tender auctions
Member states that still use uncapped negative bidding should heed the call in the EU’s Wind Power Package to avoid such auctions. They should instead shift towards models that offer more predictable returns and lower financing costs for developers, such as long-term power purchase agreements that guarantee stable prices and predictable cash flow for developers.
Governments should also set out a plan for a stable pipeline of wind energy auctions or tenders to provide developers and investors with greater certainty on volumes and revenues. The North Seas Energy Cooperation has provided a useful model for such coordination, where governments align on long-term planning of offshore wind growth and collaborate on joint projects.
Developing resilient and secure supply chains
Support domestic production
The EU and European countries need to develop domestic wind production to lower dependencies on single sources. While it is not feasible for them to remake a fully integrated wind industry supply chain, this reduction is achievable over time.
This would not necessarily involve excessive amounts of new financial support through one-off state-aid or grants. European wind turbine manufacturers and component suppliers, for example, have called for production-based incentive schemes to stimulate investment for the long term. The European Commission could test how this would work without developing unfair competition between member states.[9]
But the EU and member states should ensure such support helps relieve critical dependencies. Crucially, the EU and its member states need to overcome their reliance on China for permanent magnets. The Critical Raw Materials Act and the Net Zero Industry Act set targets and simplify permitting to encourage investment in developing a rare-earth supply chain for technologies that require such materials. Some important European magnet makers have already been attracted by the benefits offered by the IRA in the US. But Europe has building blocks of its own to exploit.
The EU should bolster the development of new rare earths processing under way in France and Norway, as well as Estonia’s and other nascent magnet manufacturing sectors. The bloc should do this by leveraging state aid and EIB financial support for critical raw materials to facilitate guaranteed purchases between these new rare earth production efforts and wind industry end users.
The EU will also need financial protections against any Chinese monopolistic pressures the European processing and magnet industries may face. The EU should also support the efforts of its Japanese, Australian and South-East Asian partners to develop new mine and separation capacities for the earlier stages of the permanent magnet supply chain. This would enable all involved to diversify their trade.
Foster alternative supply chains
In parallel with new domestic production, the European wind energy sector needs alternative supply chains for components for which it is currently dependent on China. This will help ensure fair competition, and sustainable and resilient growth in the sector. Europeans should focus on such critical components as gearboxes, generators and power converters, which are at risk of concentration in China. Policymakers and industry figures should collaborate with partners that share the EU’s goals of developing home-grown clean technology industries, reducing dependence on China, and building resilient and competitive supply chains. The EU would be well placed to share its expertise on permit reform and grid connectivity with third markets facing similar challenges.
India stands out as a promising candidate for such collaboration. Its potential as a manufacturing base suffers due to swings in annual domestic demand and high wind turbine costs compared with China. But India’s large and fast-growing wind energy market offers one of the most attractive low-cost destinations outside China, boasting an industry ecosystem and policies that promote local wind turbine production.
The EU, UK and India should work together to ensure mutual market access for their respective wind technologies. They should also introduce safeguards against distortions caused by subsidised products or trade diversion. Such coordination is essential if industries in both Europe and India are to grow and remain competitive against China’s clean technology giants. The EU-India Trade and Technology Council offers an established platform to advance this collaboration. The UK government should consider replicating its ongoing policy and research collaboration with China on offshore wind, for example UK-China Offshore Wind Industry Advisory Group, with India.
Take control of wind turbines
The EU and its member states should ensure that control of turbines and access to operational software can only originate from the EU countries. One way to implement this safeguard would be to include such requirements in the pre-qualification criteria for renewable energy auctions under the Net Zero Industry Act and through national auction frameworks. Lithuania, for example, has passed legislation that bans access to management systems of solar and wind farms by companies from countries that pose a threat to national security. The law prohibits these entities from remotely managing key operational functions, such as adjusting electricity output or turning systems on and off. This could provide a model for other member states.
Over the horizon
If the EU wishes to continue playing a role in promoting the green transition and expanding clean technologies worldwide, it must first take command of its green future at home. European governments must identify where Chinese wind turbine manufacturers have gained competitive advantages through state support. Europeans should then aim their policy interventions at closing these gaps through trade defence measures, regulations and incentives.
But it cannot stop there. Overseas markets are crucial for European wind turbine manufacturers to remain competitive in the long term. It will be vital for the EU and member states governments to foster and deepen international partnerships that can help them maintain resilient supply chains, thereby assuring Europe’s energy security and strategic autonomy.
About the authors
Luke Patey is a senior researcher at the Danish Institute for International Studies, focusing on geoeconomics and industrial competitiveness in green and digital technologies.
Byford Tsang is a senior policy fellow with the Asia programme at the European Council on Foreign Relations. He previously led the China programme at the international climate think tank E3G, where he advised policymakers on EU-China negotiations on climate and energy issues.
Acknowledgments
The authors would like to thank the participants in the ECFR workshop in Berlin in early 2025, as well as colleagues from the wind industry who generously shared their insights in interviews. We are also grateful to ECFR’s Sonia Li for her research support, Janka Oertel for her intellectual guidance and Kim Butson for her excellent editing support.
[1] ECFR workshop, held under the Chatham House rule, Berlin 2025.
[2] Authors’ interviews with wind industry insiders, online, February 2025.
[3] Authors’ interview with wind industry insiders, online, February 2025.
[4] Authors’ interview with Chinese manufacturer, online, February 2025.
[5] Authors’ interview with European investors, online, April 2025.
[6] Authors’ interview with industry insiders, online, November 2024.
[7] Author interview with European supplier, online, May 2025.
[8] Authors’ interview with Western manufacturer, online, April 2025.
[9] Author interviews, online, November 2024 and May 2025.
The European Council on Foreign Relations does not take collective positions. ECFR publications only represent the views of their individual authors.
Bernardo Silva is refusing to look at Manchester City’s shock exit from the Club World Cup as a blessing in disguise.
The Premier League outfit crashed out of the competition in the early hours of Tuesday morning as they were beaten 4-3 in extra time by Saudi outfit Al-Hilal after a pulsating last-16 clash in Orlando.
City had established themselves as one of the favourites to triumph in the United States after winning all three of their group games in convincing fashion.
A run to the final would have prolonged their campaign until July 13, however, just five weeks before the next Premier League season begins.
After much debate about the impact of the Club World Cup on player welfare, there is a feeling in some quarters that City – after an underwhelming 2024-25 season – need the rest, but Silva does not see it that way.
The City captain said: “No-one wanted to lose. We are very used to not having holidays, unfortunately, because the schedule is crazy and when we are in a competition we take it very seriously.
“We had a lot of ambition for this Club World Cup and we wanted to win it.”
Al Hilal celebrated as Man City were left bereft (REUTERS)
Asked if the defeat hurt as much as Champions League elimination, Silva said: “Yes, a little bit. Yes.”
City had taken early control with a ninth-minute goal from Silva at the Camping World Stadium, but they were to rue missing a succession of chances to increase the lead before the break.
Al-Hilal turned the game around through Marcos Leonardo and Malcom and reclaimed the advantage again with a Kalidou Koulibaly header after Erling Haaland forced extra time.
Get 4 months free with ExpressVPN
Servers in 105 Countries Superior Speeds Works on all your devices
Try for free
ADVERTISEMENT. If you sign up to this service we will earn commission. This revenue helps to fund journalism across The Independent.
Get 4 months free with ExpressVPN
Servers in 105 Countries Superior Speeds Works on all your devices
Try for free
ADVERTISEMENT. If you sign up to this service we will earn commission. This revenue helps to fund journalism across The Independent.
Phil Foden made it 3-3, but City could not regain the initiative and Leonardo settled an eventful contest – and secured a statement victory for Saudi football – with 112 minutes on the clock.
Silva said: “There was always a feeling of danger coming from them when they recovered the ball in transition and their counters. We allowed them to run way too many times.
“But apart from that we had chances. We scored three goals and we could have scored five or six.
“They punished us. They have a good team with a lot of individual quality and congratulations to them.”
Silva insisted the Club World Cup exit was a painful experience (AP)
Former Wolves midfielder Ruben Neves impressed in the Al-Hilal midfield and fellow Portuguese Joao Cancelo was a threat against his old City team-mates.
Silva, also a Portugal international, said: “I have friends there, I know most of their players and I know the quality they have.
“We were expecting another difficult game like Juventus and when you don’t control transitions then good players, like Al-Hilal have, punish you. That’s what happened.”
City begin the new Premier League season at Wolves on August 16.
Silva said: “We will try to have as much rest as possible but also come back to prepare for the season properly.”
Watch every Fifa Club World Cup game free on DAZN.
The emergency power generators based on 20-cylinder mtu Series 4000 P63 engines, each with an output of 2,600 kWe, ensure that the power supply on the converter platforms remains stable even if the main power supply fails. They also ensure that control and monitoring systems continue to operate, that the infrastructure of the service crew quarters is maintained, and that lighting and other safety-critical systems do not fail. They also supply power for cooling and ventilation of important system components to prevent damage from overheating. In extreme cases, the emergency power generators enable the systems to be shut down and restarted in a controlled manner.
“The engines have to be extremely reliable because they are the piece of the puzzle that matters when it comes down to it,” explained Detlev Köster, Sales Manager in the Offshore business at Rolls-Royce Power Systems. “We are delighted that Eureka Pumps is continuing to rely on our products in project phase 2.”
Rolls-Royce secures critical infrastructure worldwide in line with its strategy: The company offers mtu emergency power solutions based on diesel and gas generators as well as dynamic uninterruptible power systems (UPS). In addition to offshore platforms, these include data centers, industrial plants, airports, hospitals, power plants, and numerous other facilities that require an uninterruptible power supply.
A recent study involving researchers from the University of Basel reveals that slowing down the intracellular transport of RNA-based drugs can significantly enhance their effectiveness. These promising therapeutics are currently used to treat rare genetic diseases.
In modern medicine, personalized therapies are becoming increasingly important – particularly in the treatment of genetic diseases. One such promising approach is the use of so-called antisense oligonucleotides (ASOs). These small, synthetic molecules specifically interfere with cell metabolism by preventing the production of disease-causing proteins. Such RNA-based therapies are already being used successfully to treat previously incurable genetic disorders such as amyotrophic lateral sclerosis (ALS) and Duchenne muscular dystrophy.
Limited efficacy of RNA-based drugs
A key challenge, however, is that most ASOs fail to reach their intended target within the cell and thus cannot achieve their full therapeutic potential. In a collaborative study published in “Nature Communications”, an international research team – including Professor Anne Spang from the Biozentrum of the University of Basel and scientists from Roche – used CRISPR/Cas9 technology to identify factors that significantly influence ASO activity. The findings open new avenues for improving RNA therapy efficacy and accelerating their development.
Antisense nucleotides are tiny, custom-designed genetic fragments that bind specifically to RNA molecules within the cell, thereby interfering with protein synthesis. Once administered, most ASOs are taken up by the cell and reach the cell’s sorting stations, so-called endosomes, via small transport vesicles. To exert their therapeutic effect, they must escape from the endosomes. Otherwise, they are declared as “cellular waste” and quickly shuttled to lysosomes for degradation. Since only a small fraction of ASOs manage to escape, their overall efficacy is limited.
Residence time in endosomes as a critical factor
The likelihood of ASOs escaping from the endosomes is closely linked to the speed of intracellular transport: the longer they remain in the endosome, the more time they have to escape. Using a genome-wide CRISPR/Cas9 screen, the researchers systematically knocked out thousands of genes to investigate their impact on ASO efficacy.
We identified a large number of genes that either improve or impair ASO activity. Many of these genes are involved in the intracellular transport of ASOs.”
Dr. Liza Malong, lead author and researcher at Roche
The team also discovered that the gene AP1M1 plays a key role in this process: it regulates the transport from the endosome to the lysosome. “By selectively switching off this gene, ASOs remain longer in specific endosomes,” explains senior co-author Dr. Filip Roudnicky, also a researcher at Roche. “This prolonged residence time increases their chance of escaping from the endosomes and becoming effective.” In both cell cultures and a mouse model, this approach significantly improved ASO efficacy without requiring an increased dosage.
Toward more effective RNA-based therapies
The study provides a comprehensive overview of genes that modulate ASO activity and demonstrates that slowing down endosomal transport can boost the therapeutic efficacy of ASOs. “The key to more effective therapies thus lies not only in the drug itself, but also in intracellular trafficking,”adds Anne Spang. “This concept may also apply to other drugs and even to bacterial and viral pathogens.Shortening the residence time of pathogens in endosomes could reduce their chance of escaping and replicating within the cell. This might represent a novel strategy in the fight against infections.”
Source:
Journal reference:
Malong, L., et al. (2025). A CRISPR/Cas9 screen reveals proteins at the endosome-Golgi interface that modulate cellular anti-sense oligonucleotide activity. Nature Communications. doi.org/10.1038/s41467-025-61039-y.
Sainsbury’s has recorded its strongest growth since last summer after its Argos chain recorded a big step up in sales as shoppers sought out paddling pools and fans during recent hot weather.
The retail group said Argos, its catalogue shop, was able to achieve growth of 4.4% in the three months to 21 June, up from 1.9% in the previous quarter. Comparable group sales, excluding fuel, rose 4.7% on a year earlier.
The group’s total sales rose 4.9%, helped by the strong trading at Argos and a rise in clothing sales as shoppers snapped up shorts and swimsuits, as well as healthy demand for its premium food ranges. That excludes fuel, where sales fell partly because of price decreases.
The retailer said it had achieved the strong sales despite a “subdued, highly competitive and deflationary general merchandise market” as it booked rapid growth in online sales and via its app. Sales in stores declined, partly because of further closures as many Argos sites move from high streets into Sainsbury’s supermarkets.
Sainsbury’s, the UK’s second biggest supermarket chain, said it had cut prices compared with all “key competitors” as it was on track to cut £1bn in costs by March 2027. Costs were partly lowered by a shift to self-service tills and SmartShop handsets, with which shoppers scan goods in their basket on the go.
The figures indicate that Sainsbury’s is holding out against a wave of price cuts and improved service at Asda, the UK’s third largest supermarket chain, which aims to win back shoppers after more than a year of sales declines.
Simon Roberts, the chief executive of Sainsbury’s, said: “Our winning combination of great value, outstanding quality, excellent availability and leading customer service has driven further share gains, reaching our highest market share in almost a decade.
“We have great momentum, growing faster than the market for three consecutive years and we are well set to deliver another strong performance over the summer. Boosted by a sunny spring, we’re already off to a great start,” he said.
skip past newsletter promotion
after newsletter promotion
However, the strong sales figures were helped by an increase in food inflation, which rose to 3.7% in June, up from 2.8% in May. The British Retail Consortium said hot weather, with temperatures close to record levels this month, was hitting harvest yields.
Retailers have warned since Rachel Reeves’s autumn budget that the chancellor’s £25bn increase in employer national insurance contributions and 6.7% national living wage rise, introduced from April, would force them to raise their prices.
Klebsiella pneumoniae is not only a common pathogen causing nosocomial infections but also an important cause of community-acquired infections, that colonizes human mucosal surfaces such as the nasopharynx and the gastrointestinal tract.1 In recent years, with the prevalence of multidrug-resistant and hypervirulent K. pneumoniae in the world, the incidence rate of K. pneumoniae infections has risen dramatically, such as urinary tract infection, pneumonia, liver abscess, and so on.1 Compared with the classical K. pneumoniae (cKp), hypervirulent K. pneumoniae (hvKp) possesses higher toxicity, which can cause severe infection in immunocompromised people, with high pathogenicity and mortality.2 Although many factors contribute to the high virulence of the hvKp, virulence factors, including capsule, siderophores, lipopolysaccharide, and fimbriae, play an essential role in the pathogenesis of several diseases.3–6 Numerous reports have shown that K1 and K2 serotypes are strongly associated with hvKp among 79 serotypes of K. pneumoniae.7,8 Additionally, some genes, rmpA, iutC, and ybtA, which are responsible for the production of high viscosity, iron-acquiring factors, aerobactin and yersinia actin, respectively, have been associated with the hypervirulence of K. pneumoniae.5,9 Recently, the pks (polyketide synthase) gene cluster, as a new virulence factor, has aroused great public concern.10
The pks gene cluster is a genetic locus that was first described in some Escherichia coli strains from the B2 phylogroup by Nougayrede in 2006.11 It contains 19 genes (clbA to clbS) with 54 kb and encodes a multi-enzyme complex capable of producing a genotoxin called colibactin. Previous studies have shown that colibactin can cleave host DNA double strands, resulting in cell cycle arrest, DNA damage, and mutations.12,13 Moreover, it increases the likelihood of serious complications of bacterial infections. For instance, production of colibactin by pks+E. coli exacerbates lymphopenia associated with septicemia and increases the morbidity and mortality of urosepsis and meningitis in immunocompromised mice.14,15 Additionally, pks-positive E. coli has been associated with mutations in colorectal cancer.13,16,17 Subsequently, the pks island has also been found in several other members of the Enterobacteriaceae family, such as Citrobacter koseri, K. pneumoniae, and Enterobacter aerogenes, but was found to be relatively infrequent.18–20 A study in Europe showed that the prevalence of the pks gene cluster was 34% in E. coli strains of phylogenic lineage B2, but only 3.5% in K. pneumoniae clinical isolates.18 While the predominance of pks genes in bloodstream-sourced K. pneumoniae is approximately 25.6% and 26.8% in Taiwan and Changsha, respectively,21,22 little is known about its epidemiology in clinical isolates from cancer patients in China.
Given the potential role of the pks gene cluster in cancer and its association with hypervirulence, it is crucial to investigate the prevalence and molecular characteristics of pks-positive K. pneumoniae in patients with cancer. This study aimed to address this gap by examining the presence of the pks gene cluster and analyzing the clinical and molecular features of pks-positive K. pneumoniae isolates from patients with cancer in China. Understanding the distribution and characteristics of these isolates will provide valuable insights into their pathogenic potential, and inform clinical practice and epidemic surveillance.
Materials and Methods
Bacterial Isolates Collection
A total of 279 non-repetitive clinical K. pneumoniae isolates were obtained from all cancer patients in China at Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen Center between January 2022 and June 2024. All cases were diagnosed according to the International Classification of Diseases, 10th Revision (ICD-10) and presented with clinical evidence of infection (including clinical symptoms, laboratory indicators, and microbiological evidence). These strains were isolated from diverse specimens, including sputum, blood, urine, drainage fluid, bile, catheter, gastric juice, vaginal secretion, and wound secretion. The collection, isolation, and culture of all clinical specimens must be performed under aseptic conditions and comply with the standards of CLSI (Clinical and Laboratory Standards Institute) guidelines and WHO Laboratory Biosafety Manual. After being isolated and purified, these strains were preserved at −80 °C in a tube containing 20% glycerol for a long time. The full 10 μL loop of colonies after balancing to room temperature were spread onto the Columbia blood agar (Oxoid, Brno, Czech Republic) and incubated at 37 °C for 24 h in 5% CO2 atmosphere. At the same time, the information of these patients was also collected. This study was approved by the hospital ethics committee (Approval No: JS2024-18-1).
Identification and Antimicrobial Susceptibility Testing
Isolates were identified by by matrix-assisted laser desorption-ionization time-of-flight mass spectrometry (MALDI-TOF MS; bioMerieux SA, Lyons, France) according to the manufacturer’s protocol. Antimicrobial susceptibility testing was performed using automatic microbial identification and the antibiotic sensitivity analysis system, Vitek 2 Compact (bioMerieux SA, Lyons, France). The results of the antibiotic sensitivity test were determined based on the breakpoints recommended in the guidelines of the 2023 Clinical and Laboratory Standards Institute (CLSI).
Identification of the Pks Gene Cluster in Clinical K. pneumoniae Isolates
Genomic DNA was extracted from 279 clinical isolates using a bacterial DNA extraction kit (Tiangen Biochemical Technology, Beijing, China) and quantified using Qubit 4.0 according to the manufacturer’s instructions. PCR was used to detect pks genes (clbA, clbB, clbN, and clbQ). The primers and amplification conditions used in the present study for pks detection are listed in Table 1.11 The PCR products were visualized using 2% agarose gel electrophoresis.
Table 1 Primers Used for Amplification of the Tested Pks Genes
The positive of pks gene clusters were verified by blasting whole genomic coding ORFs against E. coli clb reference genes (GenBank accession: AM229678.1)11 with both identity and coverage threshold greater than 80%.
Whole-Genome Sequencing and Analysis
A total amount of 0.2 μg of DNA per sample was used as input material for DNA library preparations using the Rapid Plus DNA Lib Prep Kit (RK20208) (Beijing Baiao Innovation Technology, China). Subsequently, the library quality was assessed on the Agilent 5400 system (AATI) and quantified by real-time PCR (1.5 nM). The qualified libraries were pooled and sequenced on Illumina platforms (Illumina, San Diego, CA, USA). Sequencing reads were assembled using Shovill (1.1.0) (https://github.com/tseemann/shovill), and the contamination and completeness of the assembled genome were assessed using CheckM (v1.2.2).23 Whole-genome annotation was performed using the Prokka software (1.14.6).24
SNP distance and phylogenetic tree construction were performed for pks-positive strains. Phylogenetic analysis was conducted using IQ-TREE software (version 2.3.5) and visualized with the ggtree package in R (version 4.4.2). The K159 strain was used as the reference genome, and core genomic SNPs (cgSNPs) were identified using Snippy (v4.6.0) (https://github.com/tseemann/snippy).
Sequence types (ST) and serotypes were determined from whole-genome data using Kleborate (2.2.0)25 against pubMLST database26 and Kaptive database.27
Virulence genes and antibiotic resistance genes were identified using the ABRicate (1.0.1)28 and AMRFinderPlus (3.11.14)29 from genome assembly, respectively.
Statistical Analysis
All analyses were performed with the Statistical Package for the Social Sciences version 28.0 (SPSS, Chicago, IL, USA). Significance of differences in frequencies and proportions was tested by the χ2 test or Fisher’s exact test. A P-value <0.05 was considered statistically significant.
Results
Clinical Characteristics of Pks-Positive K. pneumoniae
Among 279 K. pneumoniae isolates, 35 (12.54%) pks gene cluster positive representatives were identified, which were mainly isolated from the sputum (20, 57.14%). The clinical characteristics of the patients who isolated K. pneumoniae isolates are presented in Tables S1 and S2. The average age of patients with pks-positive K. pneumoniae was 59, and most of them were male (27, 77.14%). And the diagnosis of lung cancer (15, 42.86%) was predominant in patients harbouring pks-positive isolates, followed by gastric cancer (3, 8.57%). But comparing with patients infected by pks-negative K. pneumoniae, there was no significant difference in age, specimen source, infections position, and sexes in patients harbouring pks-positive isolates (P > 0.05) (Table 2).
Table 2 Clinical Data of Patients Infected with Pks-Positive and Pks-Negative K. pneumoniae
Antimicrobial Susceptibility of Pks-Positive Isolates
There was no significant difference in rates of susceptibility between the pks-positive and pks-negative K. pneumoniae isolates to most antibiotics, including β-lactam/β-lactamase inhibitors, fluoroquinolones, cephamycin, aminoglycosides, and carbapenems, except for sulfonamides (Tables S3 and S4). For example, the susceptibility rates of cefoperazone sulbactam, piperacillin tazobactam, cefuroxime, ceftazidime, ceftriaxone, cefepime, amikacin were 100%, 85.71%, 74.29%, 91.43%, 85.71%, 88.57%, and 100% in the pks-positive K. pneumoniae, and compared with the pks-negative K. pneumoniae, where the respective rates for these antibiotics were 95.90%, 88.52%, 72.95%, 84.02%, 77.05%, 84.02%, and 98.36% (Table 3). Although there was a tendency that the pks+K. pneumoniae isolates were less resistant to carbapenem agents tested versus pks-isolates (100% vs 98.36%), the difference was insignificant. Sulfamethoxazole was the only agent to which pks-positive isolates were significantly more susceptible than pks-negative isolates (100% vs 75.82%, P<0.001) (Table 3).
Table 3 Susceptibility of Pks-Positive and Pks-Negative K. pneumoniae to Antimicrobials
Molecular Characteristics of Pks-Positive K. pneumoniae
In this study, whole-genome sequencing of 35 pks+K. pneumoniae isolates was performed, and the detailed quality assessment results are shown in Table S5. The average genome size of 35 pks+K. pneumoniae isolates was 6.02 Mbp, and the average GC content was 57.38%. The average largest were 0.72 Mbp, and N50 scaffolds were 0.29 Mbp in length, indicating the high assembling quality. The result of genome sequencing showed that virulence associated serotype K1 (17, 48.57%) was the predominant serotype, and K2 accounted for 25.71% in pks-positive K. pneumoniae (Figure 1). Six other K serotypes (K116 (3), K113 (2), K20 (1), K25 (1), K57 (1), and K62 (1)) accounted for 25.72% of isolates.
Figure 1 Phylogenetic tree based on SNP sites in core genes of 35 pks-positive strains.
Among the 35 pks-positive K. pneumoniae, the multilocus sequence typing showed that the predominant sequence types were ST23 (19, 54.29%) and ST65 (8, 22.86%), while another six STs each had no more than 3 strains, ST133 (3, 8.57%), ST268 (1, 2.86%), ST348 (1, 2.86%), ST380 (1, 2.86%), ST592 (1, 2.86%), and ST792 (1, 2.86%) (Figure 1). The whole genomic phylogeny and SNP distance were inferred, and we found that there is no direct and recent transmission (cgSNP differences less than 20) among ST23 and ST65 isolates (Figure 1).
Virulence genes were prevalent in pks-positive isolates, particularly the siderophore systems (aerobactin, enterobactin, salmochelin, and yersiniabactin) which played different roles in infection within the host. In 35 pks-positive isolates, Enterobactin synthase genes (entAB, fepC) and yersiniabactin siderophore system genes (ybtA/E/P/Q/S/T/U/X, irp1, irp2) were at least 97.14%, meanwhile the aerobactin siderophore synthesis system genes (iucA/B/C/, iutA) and salmochelin genes (iroB/C/D/N) were at least 85.71% (Table 4). Furthermore, rmpA genes, which were the positive regulator of the mucoid phenotype, and peg-344, which could encode an intracellular transporter protein, were, respectively, found in 62.86% and 54.29% of pks-positive isolates (Table 4).
Table 4 Virulence Genes and Drug Resistance Genes of Pks-Positive K. pneumoniae
As for antibiotic resistance genes, pks-positive isolates harbored some β-lactamase genes, including blaCTX-M, blaTEM, and blaSHV. Only four isolates proved positive for CTX-M-1 group, and two isolates proved positive for CTX-M-9 group. Additionally, the screen of SHV β-lactamase genes showed that the frequencies of SHV-11, SHV-75, SHV-26, and SHV-207 were 30 (85.71%), 3 (8.57%), 1 (2.86%), and 1 (2.86%), respectively. And only two isolates were blaTEM-1 positive. However, no pks-positive isolates proved positive for the genes that confer resistance towards carbapenems.
Discussion
The pks gene island, encoding the genotoxin colibactin, has garnered significant attention due to its ability to induce DNA double-strand breaks and transient G2-M cell cycle arrest in host cells.12 This genotoxic activity suggests that colibactin may contribute to various disease entities, including newborn meningitis, urinary tract infections, bloodstream infections, and potentially cancer development.15,22,30 In addition, some studies reported that the pks-positive E. coli was more highly represented in CRC patients and could promote human CRC development.17,31 Our study is the first to investigate the prevalence and molecular characteristics of K. pneumoniae harboring the pks island in Chinese cancer patients, providing valuable insights into its epidemiology and clinical significance in this specific population.
Up to now, there have been few epidemic reports on emerging pks-positive K. pneumoniae. In Europe and Iraq, the occurrence of pks-positive K. pneumoniae was 3.5%18 and 7.14%,20 respectively. In this study, the prevalence of the pks gene cluster among K. pneumoniae isolates was 12.54%, which was higher than those reported in the literature. But in two previous studies conducted in Taiwan and Changsha, the positive rates of pks-positive K. pneumoniae isolated from blood was 16.8%32 and 26.8%,22 respectively. And some studies revealed that the prevalence of pks gene in E. coli was high, ranging from 29.2% to 72.7%.31,33,34 Therefore, we found that the epidemiological distribution of pks-positive strains exhibits regional and interspecies differences, which may be associated with environmental, host, and pathogen factors.
Colibactin encoded by the pks gene cluster has been shown to induce host DNA damage, thus may contribute to higher mutation rates that drive the occurrence of tumors. By analyzing 3668 Dutch samples of different cancer types, a study found that the colibactin was present in a variety of tumors.35 Our findings backed up the above results, which documented pks-positive K. pneumoniae had been isolated from different types of cancer patients. Jens Puschhof et al proved that the pks gene cluster was present at a higher frequency in colorectal cancer compared to other types of cancer.35 And the presence of pks-positive K. pneumoniae has been found in 4–27% colon cancer patients.18,21,32,36 However, our findings revealed that pks-positive K. pneumoniae isolates were predominantly associated with lung cancer patients (42.86%), followed by gastric cancer, which was different from the above researches that reported higher prevalence in colorectal cancer patients. This may be due to the specific patient population and sampling bias, as only parenteral specimens were collected. However, this highlights the potential role of pks-positive K. pneumoniae in various types of cancer, not limited to colorectal cancer. Further studies are needed to elucidate the specific mechanisms by which pks-positive K. pneumoniae contributes to cancer development and progression.
There are many similarities between pks-positive K. pneumoniae and hvKp. Firstly, previous studies have revealed that hvKp were almost exclusively of serotype K1 or K2, and ST23 and ST65 were predominant sequence types.5,7 On the other hand, the hvKp K1 strains were strongly associated with ST23, while the hvKp K2 strains belong to different STs (ST65, ST86, and others).5,8 In our study, the great majority (74.28%) of pks-positive isolates belonged to K1 or K2 serotype. And all K1 strains belong to ST23, whereas K2 strains were divided into two major clades, ST65 and ST380. To investigate whether there is transmission or possible outbreaks among single ST isolates, whole-genomic phylogeny and SNP distance were inferred, and we found that there is no direct and recent transmission (cgSNP differences less than 20) among ST23 and ST65 isolates, suggesting the patients get these infections from different sources. Two ST133 isolates, k130 and k131, showed almost no cgSNP differences (Figure 1), suggesting direct transmission among their host patients. However, the mechanism of transmission still needs further study. Secondly, another study suggested that hvKp were positive for several virulence factors, such as iucA, iroB, peg-344, rmpA, and so on.5,7 Our study found that pks-positive isolates generally carried several virulence genes. Additionally, the high prevalence of rmpA and peg-344 genes indicates that these isolates may exhibit a mucoid phenotype, which is associated with increased resistance to phagocytosis and host immune responses.5 Therefore we assumed that the emerging pks genotoxic trait is associated with the virulence genes of hvKp. We also found that the pks-positive strains in this study showed high sensitivity to most antibiotics, which is likely due to the fact that most of these isolates belong to K1 and K2 serotype to protect bacteria from phagocytosis and inhibit the host immune response. And compared with pks-negative strains, pks-positive strains showed higher sensitivity to sulfamethoxazole (P<0.05), which provided an important reference for antibiotic treatment. Although the rate of MDR in pks-positive isolates is low at present, the presence of β-lactamase genes, such as blaCTX-M, blaTEM, and blaSHV, indicates that these isolates have the potential to develop multidrug resistance. Therefore, continued surveillance of antimicrobial resistance patterns in pks-positive K. pneumoniae is essential to guide appropriate treatment strategies and prevent the emergence of multidrug-resistant strains.
While our study provides important insights into the prevalence and molecular characteristics of pks-positive K. pneumoniae in cancer patients, several limitations should be acknowledged. The sample size was relatively small, and only parenteral specimens were included, which may limit the generalizability of our findings. Additionally, the study was conducted in a single center, and further multicenter studies with larger sample sizes are needed to confirm our results.
Recently, it was described that the exposure to pks-positive E. coli is responsible for mutational signature in colorectal cancer, so it seems that pks-positive bacteria can induce mutation of CRC driver genes and, therefore, pks may become a marker of CRC carcinogenesis and therapy.31 Future research should focus on elucidating the specific mechanisms by which pks-positive K. pneumoniae contributes to cancer development and progression. Additionally, longitudinal studies are needed to monitor the evolution of antimicrobial resistance in these isolates and to develop targeted therapeutic strategies.
Conclusion
Our study highlights the potential pathogenicity of pks-positive K. pneumoniae in cancer patients in China, emphasizing the need for close clinical attention and epidemic tracking. The findings underscore the importance of continued surveillance and research to better understand the role of this genotoxic pathogen in cancer-associated infections.
Ethics Statement
This study was approved by the ethics committee of Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen Center (Approval No. JS2024-18-1). This study was retrospective and associated with bacterial drug susceptibility and the genetic information of the specimens, hence our ethical petition for exemption from informed consent was accepted. All patients have been informed that their samples will be used for research and have signed informed consent for sample collection. The data of all patients in this study were collected anonymously and ensured the confidentiality of their information. This study was conducted in accordance with the guidelines set out in the Declaration of Helsinki.
Acknowledgments
We gratefully acknowledge the support and resources provided by the Microbiology Laboratory, Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen Pathogen Infection Research Alliance (SPIRA) and Department of Clinical Laboratory, Shenzhen Third People’s Hospital.
Funding
This research was supported by Sanming Project of Medicine in Shen zhen (No.SZSM202311002) and Science and Technology Program of Shenzhen (Grant Nos. KCXFZ20230731100901003, KJZD20230923115116032, JCYJ20210324131212034).
Disclosure
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1. Wang G, Zhao G, Chao X, Xie L, Wang H. The characteristic of virulence, biofilm and antibiotic resistance of Klebsiella pneumoniae. Int J Environ Res Public Health. 2020;17(17):6278. doi:10.3390/ijerph17176278
2. Choby JE, Howard-Anderson J, Weiss DS. Hypervirulent Klebsiella pneumoniae – clinical and molecular perspectives. J Intern Med. 2020;287(3):283–300. doi:10.1111/joim.13007
3. Zhang QB, Zhu P, Zhang S, et al. Hypervirulent Klebsiella pneumoniae detection methods: a minireview. Arch Microbiol. 2023;205(10):326. doi:10.1007/s00203-023-03665-y
5. Russo TA, Marr CM. Hypervir ulent Klebsiella pneumoniae. Clin Microbiol Rev. 2019;32(3):e00001–19. doi:10.1128/CMR.00001-19
6. Zhu J, Wang T, Chen L, Du H. Virulence factors in hypervirulent Klebsiella pneumoniae. Front Microbiol. 2021;12:642484. doi:10.3389/fmicb.2021.642484
7. Struve C, Roe CC, Stegger M, et al. Mapping the evolution of hypervirulent Klebsiella pneumoniae. mBio. 2015;6(4):e00630. doi:10.1128/mBio.00630-15
8. Jin M, Jia T, Liu X, et al. Clinical and genomic analysis of hypermucoviscous Klebsiella pneumoniae isolates: identification of new hypermucoviscosity associated genes. Front Cell Infect Microbiol. 2023;12:1063406. doi:10.3389/fcimb.2022.1063406
9. Russo TA, Olson R, Fang CT, et al. Identification of biomarkers for differentiation of hypervirulent Klebsiella pneumoniae from Classical K. pneumoniae. J Clin Microbiol. 2018;56(9):e00776–18. doi:10.1128/JCM.00776-18
10. Luo CS, Chen YS, Hu XN, et al. Genetic and functional analysis of the pks gene in clinical Klebsiella pneumoniae Isolates. Microbiol Spectr. 2023;11(4):e0017423. doi:10.1128/spectrum.00174-23
11. Nougayrède JP, Homburg S, Taieb F, et al. Escherichia coli induces DNA double-strand breaks in eukaryotic cells. Science. 2006;313:848–851. doi:10.1126/science.1127059
12. Bossuet-Greif N, Vignard J, Taieb F, et al. The colibactin genotoxin generates DNA interstrand cross-links in infected cells. mBio. 2018;9(2):e02393–17. doi:10.1128/mBio.02393-17
13. Cuevas-Ramos G, Petit CR, Marcq I, Boury M, Oswald E, Nougayrède JP. Escherichia coli induces DNA damage in vivo and triggers genomic instability in mammalian cells. Proc Natl Acad Sci U S A. 2010;107(25):11537–11542. doi:10.1073/pnas.1001261107
14. Marcq I, Martin P, Payros D, et al. The genotoxin colibactin exacerbates lymphopenia and decreases survival rate in mice infected with septicemic Escherichia coli. J Infect Dis. 2014;210(2):285–294. doi:10.1093/infdis/jiu071
15. Bakthavatchalu V, Wert KJ, Feng Y, et al. Cytotoxic Escherichia coli strains encoding colibactin isolated from immunocompromised mice with urosepsis and meningitis. PLoS One. 2018;13(3):e0194443. doi:10.1371/journal.pone.0194443
16. de Souza JB, de Almeida Campos LA, Palácio SB, Brelaz-de-Castro MCA, Cavalcanti IMF. Prevalence and implications of pKs-positive Escherichia coli in colorectal cancer. Life Sci. 2024;341:122462. doi:10.1016/j.lfs.2024.122462
17. Sadeghi M, Mestivier D, Sobhani I. Contribution of pks+ Escherichia coli (E. coli) to colon carcinogenesis. Microorganisms. 2024;12(6):1111. doi:10.3390/microorganisms12061111
18. Putze J, Hennequin C, Nougayrède JP, et al. Genetic structure and distribution of the colibactin genomic island among members of the family Enterobacteriaceae. Infect Immun. 2009;77(11):4696–4703. doi:10.1128/IAI.00522-09
19. Morgan RN, Saleh SE, Farrag HA, Aboulwafa MM. Prevalence and pathologic effects of colibactin and cytotoxic necrotizing factor-1 (Cnf 1) in Escherichia coli: experimental and bioinformatics analyses. Gut Pathog. 2019;11:22. doi:10.1186/s13099-019-0304-y
20. Hussein MT, Qaysi SA, Rathi MH, Moussa T. prevalence and characterization of some colibactin genes in clinical enterobacteriaceae isolates from Iraqi patients. Baghdad Science Journal. 2020. doi:10.21123/bsj.2020.17.3(Suppl.).1113
21. Lai YC, Lin AC, Chiang MK, et al. Genotoxic Klebsiella pneumoniae in Taiwan. PLoS One. 2014;9(5):e96292. doi:10.1371/journal.pone.0096292
22. Lan Y, Zhou M, Jian Z, Yan Q, Wang S, Liu W. Prevalence of pks gene cluster and characteristics of Klebsiella pneumoniae-induced bloodstream infections. J Clin Lab Anal. 2019;33(4):e22838. doi:10.1002/jcla.22838
23. Parks DH, Imelfort M, Skennerton CT, Hugenholtz P, Tyson GW. CheckM: assessing the quality of microbial genomes recovered from isolates, single cells, and metagenomes. Genome Res. 2015;25(7):1043–1055. doi:10.1101/gr.186072.114
25. Lam MMC, Wick RR, Watts SC, Cerdeira LT, Wyres KL, Holt KE. A genomic surveillance framework and genotyping tool for Klebsiella pneumoniae and its related species complex. Nat Commun. 2021;12(1):4188. doi:10.1038/s41467-021-24448-3
26. Jolley KA, Maiden MC. BIGSdb: scalable analysis of bacterial genome variation at the population level. BMC Bioinformatics. 2010;11:595. doi:10.1186/1471-2105-11-595
27. Lam MMC, Wick RR, Judd LM, Holt KE, Wyres KL. Kaptive 2.0: updated capsule and lipopolysaccharide locus typing for the Klebsiella pneumoniae species complex. Microb Genom. 2022;8(3):000800. doi:10.1099/mgen.0.000800
28. Chen L, Zheng D, Liu B, Yang J, Jin Q. VFDB 2016: hierarchical and refined dataset for big data analysis–10 years on. Nucleic Acids Res. 2016;44(D1):D694–D697. doi:10.1093/nar/gkv1239
29. Feldgarden M, Brover V, Gonzalez-Escalona N, et al. AMRFinderPlus and the reference gene catalog facilitate examination of the genomic links among antimicrobial resistance, stress response, and virulence. Sci Rep. 2021;11(1):12728. doi:10.1038/s41598-021-91456-0
30. Lu MC, Chen YT, Chiang MK, et al. Colibactin Contributes to the Hypervirulence of pks+ K1 CC23 Klebsiella pneumoniae in Mouse Meningitis Infections. Front Cell Infect Microbiol. 2017;7:103. doi:10.3389/fcimb.2017.00103
31. Joo JE, Chu YL, Georgeson P, et al. Intratumoral presence of the genotoxic gut bacteria pks+ E. coli, Enterotoxigenic Bacteroides fragilis, and Fusobacterium nucleatum and their association with clinicopathological and molecular features of colorectal cancer. Br J Cancer. 2024;130(5):728–740. doi:10.1038/s41416-023-02554-x
32. Chen YT, Lai YC, Tan MC, et al. Prevalence and characteristics of pks genotoxin gene cluster-positive clinical Klebsiella pneumoniae isolates in Taiwan. Sci Rep. 2017;7:43120. doi:10.1038/srep43120
33. Kamali Dolatabadi R, Fazeli H, Emami MH, et al. Phenotypic and genotypic characterization of clinical isolates of intracellular adherent-invasive Escherichia coli among different stages, family history, and treated colorectal cancer patients in Iran. Front Cell Infect Microbiol. 2022;12:938477. doi:10.3389/fcimb.2022.938477
34. Yoshikawa Y, Tsunematsu Y, Matsuzaki N, et al. Characterization of colibactin-producing Escherichia coli isolated from Japanese patients with colorectal cancer. Jpn J Infect Dis. 2020;73(6):437–442. doi:10.7883/yoken.JJID.2020.066
35. Pleguezuelos-Manzano C, Puschhof J, Rosendahl Huber A, et al. Mutational signature in colorectal cancer caused by genotoxic pks+ E. coli. Nature. 2020;580(7802):269–273. doi:10.1038/s41586-020-2080-8
36. Lam MMC, Wyres KL, Duchêne S, et al. Population genomics of hypervirulent Klebsiella pneumoniae clonal-group 23 reveals early emergence and rapid global dissemination. Nat Commun. 2018;9(1):2703. doi:10.1038/s41467-018-05114-7
Now 57, Rowe, who subsequently got involved with cycling coaching, still feels the effects of the injury in terms of her mobility.
Keen to accentuate the positive, she says: “I can do things in adapted form and I just thank my lucky stars I am here.”
While Sarah may have been lost to the sport, in a competitive sense at least, far too early, her two children are showing plenty of signs that they, like their mum, could be heading to the top.
Her son, Elliot, 19, has been signed by cycling giants Team Visma Lease a Bike, as part of their development team, and won a bronze medal in June’s British under-23 individual time trial.
Her daughter, Melanie, 16, recently finished first in the under-17s race in the prestigious Tour of Flanders event.
“I have to say my heart is in my mouth every time they go out on the roads, but that is part of life and they just have to get on and enjoy it and be careful and be safe as best they can,” Rowe says.
“It is lovely seeing what they are doing because I can relate to it. I just love to see them enjoying the journey – it is such a special thing what the bike can give you.”
Elliot and Melanie were not born when their mum was competing at Olympic level.
However, her knowledge and experience is clearly a huge help as they aim to make their own way in the sport, with Elliot suggesting: “My mum is really modest.
“She never bigs it up too much, but we get little stories here and there, which is pretty cool, because it is just a reminder that it did happen and it is something that you will always remember and something that me and my sister would both want to work towards in the future.”
Melanie adds: “I find it really helpful because she always knows exactly how I feel about everything because she has done it before.”
If both children continue to deliver on their early promise, perhaps their mum will find herself back, as a proud parent, at an Olympic Games some day in the future.